Vaxcyte Inc PCVX shares are trading lower in Monday's after-hours session after the vaccine company announced the commencement of a proposed public offering.
What Happened: Vaxcyte commenced an underwritten public offering of its common stock and pre-funded warrants, subject to market and other conditions. The company did not provide a timeline for completion or details on the size of the offering.
Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases.
See Also: What's Going On With Moderna Stock Monday?
PCVX Price Action: Vaxcyte shares surged 16% during Monday's regular session after the company reported positive data from a Phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate.
The stock was down 5.6% after hours at $39.97 at the time of writing, per Benzinga Pro.
Photo: kkolosov from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
